Advances in Oral Biomacromolecule Therapies for Metabolic Diseases DOI Creative Commons
Qiuxia Jiao, Yuan Huang, Jinhan He

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 238 - 238

Published: Feb. 12, 2025

Metabolic diseases like obesity and diabetes are on the rise, therapies with biomacromolecules (such as proteins, peptides, antibodies, oligonucleotides) play a crucial role in their treatment. However, these drugs traditionally injected. For patients chronic (e.g., metabolic diseases), long-term injections accompanied by inconvenience low compliance. Oral administration is preferred, but delivery of challenging due to gastrointestinal barriers. In this article, we introduce available biomacromolecule for treatment diseases. The barriers oral drug strategies overcome also explored. We then discuss alleviating defects, including glucose metabolism, lipid energy such insulin, glucagon-like peptide-1 receptor agonists, proprotein convertase subtilisin/kexin type 9 inhibitors, fibroblast growth factor 21 analogues, peptide YY analogues.

Language: Английский

Advances in Oral Biomacromolecule Therapies for Metabolic Diseases DOI Creative Commons
Qiuxia Jiao, Yuan Huang, Jinhan He

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(2), P. 238 - 238

Published: Feb. 12, 2025

Metabolic diseases like obesity and diabetes are on the rise, therapies with biomacromolecules (such as proteins, peptides, antibodies, oligonucleotides) play a crucial role in their treatment. However, these drugs traditionally injected. For patients chronic (e.g., metabolic diseases), long-term injections accompanied by inconvenience low compliance. Oral administration is preferred, but delivery of challenging due to gastrointestinal barriers. In this article, we introduce available biomacromolecule for treatment diseases. The barriers oral drug strategies overcome also explored. We then discuss alleviating defects, including glucose metabolism, lipid energy such insulin, glucagon-like peptide-1 receptor agonists, proprotein convertase subtilisin/kexin type 9 inhibitors, fibroblast growth factor 21 analogues, peptide YY analogues.

Language: Английский

Citations

0